Patents Assigned to Emory University
  • System and method for mitigating international revenue share fraud
    Patent number: 11706023
    Abstract: Aspects of the subject disclosure may include, for example, a non-transitory, machine-readable medium, comprising executable instructions that, when executed by a processing system including a processor, facilitate performance of operations including receiving a call; selecting a next carrier to handoff the call; generating a call data record (CDR) for the handoff to the next carrier; encrypting the CDR using a call encryption key, thereby creating an encrypted CDR; encrypting the encrypted CDR using a committee encryption key, thereby creating a double encrypted CDR; recording the double encrypted CDR to a blockchain; and sending the call encryption key to the next carrier. Other embodiments are disclosed.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: July 18, 2023
    Assignees: AT&T Intellectual Property I, L.P., Emory University
    Inventors: Divesh Srivastava, Yaron Kanza, Tamraparni Dasu, Teddy Chu, Shuaicheng Ma, Li Xiong
  • Modulators of liver receptor homologue 1 (LRH-1) and uses
    Patent number: 11691939
    Abstract: This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: July 4, 2023
    Assignee: Emory University
    Inventors: Eric Ortlund, Suzanne Mays, Nathan Jui, Autumn Flynn, Michael Dugan
  • Antibacterial compounds
    Patent number: 11690824
    Abstract: The present application provides compounds of formula: Methods of using these compounds for killing bacterial growth and treating bacterial infections are also provided.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: July 4, 2023
    Assignees: The General Hospital Corporation, Rhode Island Hospital, A Lifespan-Partner, Emory University
    Inventors: Frederick M. Ausubel, Wooseong Kim, Eleftherios Mylonakis, William M. Wuest
  • BLOOD DNA METHYLATION BIOMARKER DIAGNOSTIC TEST FOR ANXIETY AND DEPRESSIVE DISORDERS
    Publication number: 20230203574
    Abstract: A method for diagnosing or giving a prognosis for anxious temperament or trait-like anxiety in a human or non-human primate subject comprising the steps of (a) obtaining DNA from a blood or saliva sample from the subject and (b) quantifying methylation in a set of differentially methylated regions (DMRs) selected from SEQ ID NOs: 1-32, 34-44, 46-53, and 55-74, GCTCA, CGCACCG, AGAGGCAG, and AGCTCG or DMR-associated genes selected from DIP2C, GRB10, INPP5A, C17ORF97, PDXK, CACNA2D4, TRAPPC9, CRTC1, MEGF6, HIVEP3, OPCML, PITPNM2, ZFPM1, RAP1GAP2, NFATC1, RNF126, FSTL3, GNAS, SH3BP2, NEURL1B, MAD1L1, HSPA12B, IGF2, PEG10, PEG3, SLC16A3, SYTL1, and ZIM2, wherein a significant change methylation indicates the present of anxious temperament or trait-like anxiety, wherein the change is relative to DNA from a second human or non-human primate who does not have anxious temperament or trait-like anxiety.
    Type: Application
    Filed: November 22, 2022
    Publication date: June 29, 2023
    Applicants: Wisconsin Alumni Research Foundation, Emory University
    Inventors: Reid Spencer Alisch, Pankaj chopra
  • Methods of managing conditioned fear with neurokinin receptor antagonists
    Patent number: 11672790
    Abstract: This disclosure relates to managing conditioned fear and conditions induced by experiencing or witnessing an extreme traumatic event using neurokinin receptor antagonists. In certain embodiments, the disclosure relates to methods of treating or preventing conditioned fear comprising administering an effective about neurokinin 3 receptor antagonist to a subject in need thereof. In certain embodiments, the subject is diagnosed with Post-Traumatic Stress Disorder.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: June 13, 2023
    Assignee: Emory University
    Inventors: Kerry J. Ressler, Raul Andreo Gali
  • Polypeptides for managing viral infections
    Patent number: 11666630
    Abstract: Antiviral polypeptides and methods of use are provided herein. In particular, these polypeptides can comprise the Yodha amino acid sequence, variants, derivatives, or truncated versions thereof. In certain embodiments, this disclosure relates to uses of the peptides, nucleic acid molecules, and compositions disclosed herein to treat or prevent a viral infection.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: June 6, 2023
    Assignees: Emory University, Rajiv Gandhi Centre for Biotechnology
    Inventors: Sanil George, Joshy Jacob, David Holthausen, Song Hee Lee, Jessica Shartouny
  • KRAS agonists, pharmaceutical compositions, and uses in managing cancer
    Patent number: 11648221
    Abstract: In certain embodiments, this disclosure relates to KRAS agonists, pharmaceutical composition, and uses in managing cancer. In certain embodiments, the KRAS agonist is 4-(4-(2-bromoacetamido)butyl)benzoic acid, salt, prodrug, or derivative thereof. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an effective amount of a compound of Formula I, salt, prodrug, or derivative thereof, to a subject in need thereof, wherein, substituents are reported herein.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: May 16, 2023
    Assignee: Emory University
    Inventor: Xingming Deng
  • Pan-tropic entry inhibitors
    Patent number: 11649235
    Abstract: This disclosure relates to compounds according to Formula (I), salts, prodrugs and pharmaceutical formulation comprising the compound are provided herein for the treatment of CXCR4 and CCR5 related conditions. The conditions may include viral infections, abnormal cellular proliferation, retinal degeneration and inflammatory diseases, or the compounds may be used as immunostimulants or immunosuppressants. Furthermore, the compounds may be used in combination with another active ingredient selected from an antiviral agent or chemotherapeutic agent.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: May 16, 2023
    Assignee: Emory University
    Inventors: Dennis Liotta, Edgars Jecs, Yesim Altas Tahirovic, Lawrence Wilson, Stephen Pelly
  • Targeted protease compositions and uses related thereto
    Patent number: 11643662
    Abstract: This disclosure relates to targeted protease compositions and uses related thereto. In certain embodiments, the disclosure relates to nanoparticles wherein a targeting molecule is linked to the nanoparticle and wherein a catalytic domain of a protease is linked to the nanoparticle. In certain embodiments, the targeting molecule and the catalytic domain are within a single polypeptide sequence. In certain embodiments, the targeting molecule binds a molecule more highly expressed on cancer cells then non-cancerous cells, and the nanoparticles disclosed herein are used for the treatment of cancer by further attaching an anti-cancer agent to the nanoparticle or incorporating an anticancer agent within the nanoparticle.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: May 9, 2023
    Assignee: Emory University
    Inventors: Lily Yang, Xiangxue Guo
  • Cas9 nucleic acid molecules and their use
    Patent number: 11634726
    Abstract: Described are recombinant nucleic acid molecules for increased expression of Cas9 in human liver. In some embodiments, the recombinant nucleic acid molecules are provided in compositions and methods for gene editing, specifically using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR).
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: April 25, 2023
    Assignee: Emory University
    Inventors: Christopher B. Doering, H. Trent Spencer, Harrison C. Brown
  • Fusion proteins having a toxin and cancer marker, nanoparticles, and uses related thereto
    Patent number: 11633363
    Abstract: This disclosure relates to nanoparticles coated with fusion proteins comprising a domain that binds a cancer marker and a domain comprising a toxic polypeptide. In certain embodiments, the targeted cancer marker is urokinase plasminogen activator receptor (uPAR) insulin-like growth factor 1 receptor (IGF1R), EGFR, HER2, and/or other member of the ErbB family of receptors. In certain embodiments, the molecule that binds a cancer marker is an amino terminal fragment of uPA or variant capable of binding uPAR and/or IGF1 or variant capable of binding IGF1R. In certain embodiments, the toxic polypeptide is a bacterial exotoxin.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: April 25, 2023
    Assignee: Emory University
    Inventors: Lily Yang, Xiangxue Guo, Hui Mao, Wei Chen
  • N4-hydroxycytidine and derivatives and anti-viral uses related thereto
    Patent number: 11628181
    Abstract: This disclosure relates to N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment and prophylaxis of viral infections.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: April 18, 2023
    Assignee: Emory University
    Inventors: George R. Painter, David Guthrie, Gregory R. Bluemling, Michael G. Natchus
  • Elimination of hepatitis b virus with antiviral agents
    Patent number: 11629125
    Abstract: The present invention is directed to compounds, compositions and methods for preventing, treating or curing Hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: April 18, 2023
    Assignee: Emory University
    Inventors: Raymond F. Schinazi, Sebastien Boucle, Franck Amblard, Ozkan Sari, Leda Bassit
  • Gait-pace meter and methods of determining gait speed
    Patent number: 11624755
    Abstract: Embodiments of the present disclosure relate generally to systems and methods of measuring speed and, more particularly, to systems and methods of measuring gait speed using a plurality of sensors. The systems described herein may include sensing units comprising one or more motion sensors for detecting a patient walking along a testing distance. In some embodiments, a controller may calculate a gait speed based at least in part on the testing distance and on signals received from the sensors. In some embodiments, an initiation input may be provided to activate the systems. In some embodiments, the initiation input may also provide a target to which a patient can walk.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: April 11, 2023
    Assignees: Georgia Tech Research Corporation, Emory University
    Inventors: Theodore Michael Johnson, II, Leigh Nadel, Ann Vandenberg, Brian Jones, Priyanka Sadananda, Mei Ling Sharon Ang
  • Energy-efficient assistive stairs
    Patent number: 11608641
    Abstract: In a method for recycling energy from stairs, a step platform is moveable between an upper and lower position. An energy storage device, coupled to the platform, stores energy when a downward force is applied thereto, causing the step platform to move to the lower position. The energy storage device (also releases stored energy as the step platform moves from to the upper position. A controllable locking mechanism (locks the step platform in the lower position when the downward force has caused the step platform to move into the lower position. A sensor determines when a downward force has been applied to the next higher step platform. A controller signals the controllable locking mechanism to unlock the step platform when the step platform is in the lower position, and when the downward force has been applied to the next higher step platform.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: March 21, 2023
    Assignees: Georgia Tech Research Corporation, Emory University
    Inventors: Cheng-Yun Karen Liu, Sehoon Ha, Yun Seong Song, Lena Ting
  • Compositions and methods for promoting immune responses to human immunodeficiency virus
    Patent number: 11590219
    Abstract: This disclosure relates to methods of promoting immune responses against HIV and compositions related thereto. In certain embodiments, this disclosure relates to methods of vaccinating for HIV comprising administering to the subject a priming composition followed by a boosting composition. In certain embodiments, the priming composition comprises a recombinant virus such as recombinant MVA that encodes an Env protein of HIV or segment thereof. In certain embodiments, the boosting composition comprises a trimeric cyclically permuted gp120 chimeric protein reported herein or DNA encoding the same.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: February 28, 2023
    Assignees: Emory University
    Inventors: Rama Rao Amara, Andrew Jones, Raghavan Varadarajan
  • MONOMER AND MULTIMERIC ANTI-HBV AGENTS
    Publication number: 20230056135
    Abstract: The present invention is directed to compounds, compositions and methods for preventing, treating or curing hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.
    Type: Application
    Filed: October 4, 2019
    Publication date: February 23, 2023
    Applicant: Emory University
    Inventors: Raymond F. Schinazi, Franck Amblard, Bryan Cox, Che Chen, Leda Bassit
  • Cardiac valve leaflet enhancer devices and systems
    Patent number: 11571305
    Abstract: The disclosure relates to a device that is configured to be implanted on the native leaflet of a heart valve to increase its length and/or thickness and thereby to improve the valve function and reduce regurgitation. The device may include a leaflet section. The leaflet section may include a central member. The central member may include a first portion, a second portion that opposes the first portion, and a base portion disposed between the first portion and the second portion. The first section may extend from the first portion and the second section may extend from the second portion. The device may include one or more engaging members extending from the central member at an angle with respect to the first section and the second section. The second section may be larger than the first section. The leaflet section may define a three-dimensional region or a bulge.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: February 7, 2023
    Assignee: Emory University
    Inventors: Sai Muralidhar Padala, Eric Leo Sarin
  • Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
    Patent number: 11566029
    Abstract: Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.
    Type: Grant
    Filed: February 15, 2021
    Date of Patent: January 31, 2023
    Assignees: IP2IPO Innovations Limited, Emory University, Cancer Research Technology Limited
    Inventors: Alexander Bondke, Sebastian Kroll, Anthony Barrett, Matthew Fuchter, Brian Slafer, Simak Ali, Charles Coombes, James Patrick Snyder
  • LEMD3 antagonizes TGF-beta-driven Smad2/3 transcription in a stiffness-dependent fashion in both the nucleus and cytosol
    Patent number: 11541101
    Abstract: Methods and compositions for modulating transforming growth factor-beta (TGF?) biological activity in a vertebrate subject in need thereof. The methods involve administering to the vertebrate subject an effective amount of a substance capable of modulating activity of LEMD3 in the vertebrate subject to thereby modulate TGF? biological activity in the vertebrate subject.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: January 3, 2023
    Assignees: University of Virginia Patent Foundation, Emory University
    Inventors: Thomas H. Barker, Leandro Moretti, Dwight M. Chambers